Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Cholangiocarcinoma 3Urinary Bladder Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Renal Pelvis and Ureter Urothelial Carcinoma 1Rectal Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Liver Neoplasms 1Glioma 1Glioblastoma 1Colonic Neoplasms 1Breast Neoplasms 1Advanced Gastrointestinal Stromal Tumor (GIST) 1Acrocephalosyndactylia 1

Interventions

pembrolizumab 1infigratinib 1enfortumab vedotin 1Surgical Procedures, Operative 1Specimen Handling 1Nephroureterectomy 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Renal Pelvis and Ureter Urothelial Carcinoma × infigratinib × Clear all
NCT04228042 2025-01-01

Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer

M.D. Anderson Cancer Center

Phase 1/2 Terminated
15 enrolled 10 charts
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡